Earnings Per Share
EPS (Diluted)
Kailera Therapeutics EPS (Diluted) increased by 79.7% to $-3650.00 in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionEarnings Per Share
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
Higher values indicate stronger profitability even when accounting for potential share dilution.
Detailed definition
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Peer comparison
Used by all public companies to provide a realistic view of earnings per share for investors.
Metric ID:
eps_dilutedHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | -$17,983.00 | -$3,650.00 |
| QoQ Change | — | +79.7% |
| YoY Change | — | +79.7% |
Range-$17,983.00 – -$3,650.00
Avg YoY Growth+79.7%
Median YoY Growth+79.7%
EPS (Diluted) at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's eps (diluted)?
- Kailera Therapeutics (KLRA) reported eps (diluted) of $-3650.00 in Q1 2026.
- What does eps (diluted) mean?
- Earnings per share calculated as if all potential shares were issued.